
December 8, 2023
Two pancreatic cancer clinical trials now recruiting at UNC Lineberger
We have recently been added as a study location for two phase I clinical trials currently recruiting patients with pancreatic ductal adenocarcinoma (PDAC).
December 8, 2023
We have recently been added as a study location for two phase I clinical trials currently recruiting patients with pancreatic ductal adenocarcinoma (PDAC).
December 5, 2023
We are following the latest developments with COVID-19 and the recommendations by the Centers for Disease Control and Prevention.
December 5, 2023
After losing his grandfather to pancreatic cancer, Justin Ashby knew he wanted to work in a lab that focused on developing new treatments for pancreatic cancer.
December 5, 2023
What does a year look like for the UNC Lineberger Comprehensive Cancer Center? Join us as we reflect on stories from 2023 that inspired us throughout the year.
December 4, 2023
Yara Abdou, MD, Dominique Higgins, MD, PhD, and Joannie Ivory, MD, recently received career development awards from the Robert A. Winn Diversity in Clinical Trials Program.
December 4, 2023
The Parenting with Cancer Clinic at the N.C. Basnight Cancer Hospital can help parents with cancer get the help and support they need.
December 4, 2023
UNC Lineberger's Chemtai Mungo, MD, MPH, is studying the feasibility of self-administered topical therapies to treat HPV and cervical precancer among women in sub-Saharan Africa.
December 1, 2023
The San Antonio Breast Cancer Symposium features presentations outlining basic, translational, clinical and community-based study findings focused on advancing the prevention, diagnosis and treatment of breast cancer.
November 30, 2023
UNC Lineberger's Katie Hoadley, PhD, rode on the Zamboni during the Carolina Hurricanes’ Hockey Fights Cancer game.
November 30, 2023
Sarah Chaires, FNP, never thought that she would slip off the white medical provider lab coat and slip into a patient hospital gown. But everything redirected for the Chaires family when she was diagnosed with HER2-positive breast cancer.